AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier...
AbbVie and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric...
AbbVie announced that the European Commission has approved SKYRIZI for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who...
AbbVie announced the acquisition of Celsius Therapeutics, Inc., a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational...
AbbVie and Gilgamesh Pharmaceuticals announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in...
